Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 4Phase 1 3Phase 4 1Phase 3 1

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Sarcoma 6Ovarian Neoplasms 4Neurofibrosarcoma 3Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Dermatofibrosarcoma 2Vascular Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors 1Solid Tumor, Adult 1Smooth Muscle Tumor 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Relapsed Pediatric Solid Tumor 1Refractory or Recurrent Solid Tumor 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Myoepithelioma 1Liposarcoma, Myxoid 1Liposarcoma 1Histiocytoma, Angiomatoid Fibrous 1Histiocytoma 1Hemangioendothelioma, Epithelioid 1Granuloma, Plasma Cell 1Granular Cell Tumor 1Glomus Tumor 1

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 25Cyclophosphamide 24Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × pazopanib × Clear all
NCT01035658 2021-10-28

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

SCRI Development Innovations, LLC

Phase 1/2 Terminated
22 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02055690 2021-05-17

PAZOFOS

The Christie NHS Foundation Trust

Phase 1/2 Terminated
21 enrolled
Gynecologic

Ovarian Neoplasms

NCT01600573 2016-10-11

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Charite University, Berlin, Germany

Phase 1/2 Unknown
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT01238770 2016-02-10

Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer

University Hospital Heidelberg

Phase 1/2 Completed
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡